Disc Medicine, Inc. (NASDAQ:IRON) CEO John D. Quisel Sells 13,012 Shares

Disc Medicine, Inc. (NASDAQ:IRON) CEO John D. Quisel sold 13,012 shares of the firm’s stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $61.95, for a total transaction of $806,093.40. Following the transaction, the chief executive officer now directly owns 72,065 shares in the company, valued at approximately $4,464,426.75. The trade was a 15.29 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Disc Medicine Stock Performance

Shares of NASDAQ:IRON opened at $63.82 on Friday. Disc Medicine, Inc. has a 52 week low of $25.60 and a 52 week high of $77.60. The company has a market cap of $1.90 billion, a PE ratio of -16.04 and a beta of 0.75. The firm has a 50 day simple moving average of $61.89 and a 200 day simple moving average of $52.25.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.15. On average, equities analysts predict that Disc Medicine, Inc. will post -4.05 earnings per share for the current year.

Analyst Ratings Changes

IRON has been the topic of a number of research analyst reports. Morgan Stanley upgraded shares of Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price objective on the stock in a research note on Tuesday, November 5th. Stifel Nicolaus lifted their price target on Disc Medicine from $79.00 to $90.00 and gave the company a “buy” rating in a research report on Tuesday, December 10th. Raymond James raised Disc Medicine from an “outperform” rating to a “strong-buy” rating and raised their target price for the company from $66.00 to $110.00 in a research note on Monday, November 4th. Jefferies Financial Group started coverage on shares of Disc Medicine in a research report on Wednesday, October 23rd. They issued a “buy” rating and a $89.00 price target on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $85.00 price objective on shares of Disc Medicine in a research report on Tuesday, October 15th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Disc Medicine currently has a consensus rating of “Buy” and a consensus price target of $87.50.

Institutional Trading of Disc Medicine

Several institutional investors have recently made changes to their positions in the stock. Atlas Venture Life Science Advisors LLC grew its holdings in shares of Disc Medicine by 9.7% during the 2nd quarter. Atlas Venture Life Science Advisors LLC now owns 2,509,456 shares of the company’s stock valued at $113,101,000 after acquiring an additional 222,223 shares in the last quarter. Wellington Management Group LLP boosted its position in Disc Medicine by 4.8% during the third quarter. Wellington Management Group LLP now owns 1,840,226 shares of the company’s stock valued at $90,429,000 after purchasing an additional 83,731 shares during the last quarter. Frazier Life Sciences Management L.P. grew its stake in Disc Medicine by 123.5% in the second quarter. Frazier Life Sciences Management L.P. now owns 1,754,834 shares of the company’s stock valued at $79,090,000 after purchasing an additional 969,834 shares in the last quarter. Deerfield Management Company L.P. Series C increased its position in Disc Medicine by 53.8% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 1,023,265 shares of the company’s stock worth $46,119,000 after purchasing an additional 357,730 shares during the last quarter. Finally, Logos Global Management LP purchased a new stake in shares of Disc Medicine during the 2nd quarter worth about $41,690,000. 83.70% of the stock is currently owned by institutional investors and hedge funds.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.